Open AccessPB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY
Author(s) -
Daver N. G.,
Wei A. H.,
Stein E. M.,
DeAngelo D. J.,
Pathak D.,
Xu Y.,
Grzesiak S.,
Venditti A.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000850248.63603.48
Subject(s) - venetoclax , azacitidine , medicine , oncology , hypomethylating agent , myeloid leukemia , cancer , chemotherapy , myeloid , phases of clinical research , leukemia , chronic lymphocytic leukemia , biochemistry , gene expression , chemistry , dna methylation , gene